TRVI 4.05 (-2.41%)
US89532M1018BiotechnologyBiotechnology

Trevi Therapeutics (TRVI) Stock Highlights

4.05 | -2.41%
2024-12-21 06:18:34
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinsons disease.

Statistics

Range Today
4.05 4.39
Volume Today 1.74M
Range 1 Year
1.26 4.68
Volume 1 Year 152.37M
Range 3 Year
0.46 4.68
Volume 3 Year 401.62M
Range 10 Year
0.46 10.62
Volume 10 Year 472.8M

Highlights

Market Capitalization 211.24M (small)
Floating Shares 46.06M
Current Price 4.05
Price To Earnings -6.55
Price To Book 3.72
Earnings Per Share -0.44
Payout Ratio 0%

Performance

Latest -2.41%
1 Month +35.45%
3 Months +15.38%
6 Months +55.17%
1 Year +204.51%
3 Years +486.96%
5 Years +12.5%
10 Years -57.37%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.